NEW YORK (GenomeWeb) – Fitch Ratings yesterday affirmed Bio-Rad's debt ratings, including its issuer default rating of BBB-, citing the company's historically low leverage and its low debt load, which provides a cushion against higher expenses associated with internal projects. 

Fitch also said that Bio-Rad's rating outlook is stable.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.